NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
NCT05802290
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
124
Enrollment
OTHER
Sponsor class
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG:
Nivolumab 240 MG in 24 ML Injection
Sponsor
Gruppo Oncologico del Nord-Ovest